The completed assessment will:

1.  inform the site-specific roadmap for capability building during the Learning Phase (with the support of EQBMED infrastructure partners),
2. serve as a baseline for sites to track progress toward their maturity goals, and
3. create visibility into site capabilities to help trial sponsors assess interest in placing protocols at the site.

Because the EQBMED Learning Phase is focused on increasing representation of Black, Hispanic, and Latino populations, the tool specifies these groups. However, the tool itself is agnostic to the nature of diversity goals and may be tailored for use accordingly.

 Importantly, this model draws from and synthesizes substantial prior clinical trial diversity initiatives including those led by the Yale Center for Clinical Investigation (YCCI), The Clinical Trials Transformation Initiative (CTTI), The National Academy of Medicine, and Multi-Regional Clinical Trials Centers of Brigham and Women’s Hospital and Harvard (MRCT Center).